tbuckley/cabot-search huggingface dataset:
AB0017 Pilot Study on The Patterns of B Lymphocyts Infiltration in Kidney from Patients with Lupus Nephritis
Authors: G.-F. Dong, K.X. Long
Journal: Annals of the Rheumatic Diseases (2016)

Background  B lymphocytes infiltration associated ectopic lymphoid tissue (ELT) formation in situ kidney tissue had been showed to play an important role in the pathogenesis of  MRL/lpr  lupus nephritis mice model, until now there are few studies to identify the significance of them in the pathogenesis, diagnosis and treatment of human lupus nephritis (LN).  Objectives  To know the significance of B lymphocytes infiltration and associated ectopic lymphoid tissue (ELT) formation in the pathogenesis, diagnosis and treatment of human LN  Methods  The renal specimen were analyzed by light microscopy examination of routine pathology and immunohistochemistry detection of CD3+,CD20+ and CD21+ cells expression. The enrolled patients were grouped based on the WHO classification of pathology or ELT patterns. Clinical datawere collected and evaluated.  Results  89 LN patients were experienced with GC and IS combination therapy and WHO III 21, WHO IV 53 and WHO V 15. 69 cases of CD20+ cells group and 20 of CD20-cells group could be divided. comparing to CD20-group, no difference could be founded in age, sex, blood leucocytes, urine protein, C3 level, C4 level, ESR, CRP, antiDNA, acute injury index and chronic injury index of renal tissue and total remission rate (all P>0.05), but significant difference can be found in mean disease duration (CD20+group: 21.8±9.9 months VS CD20-group: 9.8±6.2 months) (P=0.045) and complete disease remission rate (CD20+group: 63.8% VS CD20-group: 90%) (P=0.047) at 6 month of treatment. With respect to B lymphocytes infiltration associated ELT formation, there was focal distribution of CD3+ T cells and CD20+B cells (type 2) in 51 cases (57.3%), scattering distribution of CD3+ T cells and CD20+B cells (type 1) in 18 cases (20.2%) and no CD20+B cells infiltration in 20 cases (22.5%) but no expression of CD21+ dendritic cells expression in all. There was longer disease duration in type 2 patients than in type 1 or type 0 patients. compared to WHO V-LN patients, there was different ELT distribution patterns in WHO III and WHO IV-LN patients, but there were no difference in ELT distribution patterns between WHO III and WHO IV-LN patients.  Conclusions  Focal distribution of CD3+ T cells and CD20+B cells (type 2 ELT)was main pattern in the renal interstitial tissue of LN patients. B cells infiltration-associated ELT formation is a predictor of longer disease duration and poor response to conventional combination therapy of high-dose GC and IS.  Acknowledgement  Acknowledgement to pathologist professor Ping Mei and the statistian He Li  Disclosure of Interest  None declared
AB0771 Osteoporosis as A Prognostic Factor for Surgery Treatment Failure in Hip Fracture Patients Treated with Internal Screw Fixation:
Authors: Ø. Berg, G. Haugeberg, A. Diamantopoulos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Arthroplasty has become the method of choice for the treatment of displaced femoral neck fractures. This because the previous treatment standard using internal fixation had an unacceptable failure rate ranging from 33–45%. One explanation may have been the presence of osteoporosis which is highly prevalent in elderly patients with hip fracture. Less is known about how osteoporosis influences bone healing and the risk of treatment failure in hip fracture patients treated internal screw fixation. <h3>Objectives</h3> The aim of this study was to investigate whether osteoporosis may predict failure of displaced femoral neck fractures treated with internal fixation. <h3>Methods</h3> Individuals over 60 years of age with a displaced fracture of the femoral neck (Garden 3 and 4) in 2004 and 2005 were retrospectively identified at the Department of Orthopedics, Hospital of Southern Norway Trust in Kristiansand. All patients were operated with two cannulated screws. All patients assessed in the present study had participated in a cross sectional study on hip fracture in southern Norway in 2004 and 2005 (1). The bone mineral density of the non-fractured femoral neck as well as the bone mineral density of the lumbar spine was measured within three days post-operatively by dual-energy x-ray absorptiometry (DEXA). Osteoporosis was defined according to the WHO definition (T-score &lt;-2.5 SD at hip and/or lumbar spine). Potential predictors of hip fracture mortality were tested using univariate and multivariate logistic regression analysis. <h3>Results</h3> 145 patients were identified (100 females, 45 males) with a mean age of 80.9 years (females 80.5 years, males 81.6 years). 63 patients (43.4%) suffered of internal fixation failure, 51 (81.0%) of them had osteoporosis. The univariate and multivariate logistic regression analysis including gender, osteoporosis and age groups and the dependent variable of the study (internal fixation failure) are presented in the table 1. <h3>Conclusions</h3> Osteoporosis appears to be strongly associated with increased risk of treatment failure in hip fracture patients treated with internal screw fixation. In adjusted analysis, only gender and osteoporosis but not age was associated with treatment failure. Thus, patients suffering of osteoporosis should not be offered internal fixation after a hip fracture. Our results should be confirmed in a large scale prospective study. <h3>References</h3> Diamantopoulos AP, Rohde G, Johnsrud I, Skoie IM, Johnsen V, Hochberg M, et al. Incidence rates of fragility hip fracture in middle-aged and elderly men and women in southern Norway. Age and ageing. 2012;41(1):86–92. <h3>Disclosure of Interest</h3> None declared
GM-CSF Controls Proliferation and Survival of the Granulocyte Lineage through the Transcription Factors STAT5A/B.
Authors: Akiko Kimura, Michael A. Rieger, WeiPing Chen, James M. Simmon, Gertraud Robinson, BingMei Zhu, John O’Shea, Timm Schroeder, Lothar Hennighausen
Journal: Blood (2008)
AB0401 Comparative Efficacy of Injection and Tablet Methotrexate Forms in Rheumatoid Arthritis Treatment
Authors: L. Myasoutova, S. Lapshina, R. Mukhina
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To evaluate comparative efficacy of injection and tablet methotrexate forms in rheumatoid arthritis treatment. <h3>Methods</h3> 23 patients were included in study group (19 women, 4 men) with moderate (47.8%) and high activity (52.2%), receiving methotrexate subcutaneously in a dose of 10 -15 mg (average dose - 11 1±5,21) 1 time per week: 11 patients were switched from methotrexate tablet form, 2 patients received leflunomide previously, 10 patients received methotrexate initially. Comparison group - 20 patients (17 women, 3 men) taking methotrexate (10 -15 mg/week, the average dose 11,6±4,89) in tablets. The groups were comparable on key parameters. Effectiveness evaluation (ACR and EULAR criteria) and tolerability of treatment was carried out every 4 weeks for 6 months. <h3>Results</h3> Significant clinical and laboratory improvement (ACR 20) was achieved in 23 patients (main group) and in 14 patients - the control group. The appearance of the first effect (ACR 20) of methotrexate subcutaneously was observed after 2 weeks of treatment in 8 (34.8%), one month therapy - 17 (73.9%) patients, in the control group at 2 weeks - in 1 (5%), after 1 month at 7 (5%) patients respectively. After 6 months of methotrexate subcutaneously treatment decrease in activity (DDAS28<sub>ESR</sub> 2,3±0,9, initial DAS28<sub>ESR</sub> 5,3±2,9) corresponds to good effect, and treatment was significantly (p&lt;0.05) better compared to the group receiving methotrexate in tablet form (DDAS28<sub>ESR</sub> 1,3±1,0, initial DAS28<sub>ESR</sub> 5,2±2,6). Adverse events occurred in 5 (21.7%) patients of the main group (alopecia, itching at the injection site, increased transaminases less than 1.5 normal) did not require discontinuation of the drug, in the control group - in 11 (55%) patients: dyspepsia, alopecia, increased transaminases, 2 (10%) patients refused from therapy <h3>Conclusions</h3> Subcutaneous administration of methotrexate in RA patients demonstrated more rapid and pronounced effect, better tolerability compared with taking the drug inside. <h3>Disclosure of Interest</h3> None declared
FRI0160 Anti-TNF Therapy in Patients with Rheumatoid Arthritis Does Not Attenuate Cutaneous TNF Activity Following A Tuberculin Skin Test
Authors: R. Byng-Maddick, C. Haas, M. Ehrenstein, M. Noursadeghi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-TNF therapy has revolutionised treatment of rheumatoid arthritis (RA). This success is partly tempered by the substantially increased risk of granulomatous infectious diseases, particularly tuberculosis (TB). However the mechanisms underlying the effectiveness of the treatment are poorly understood. We used the tuberculin skin test (TST) as an in vivo challenge model to investigate whether TNF activity is attenuated by anti-TNF therapy in a prototypic cell mediated immune response. <h3>Methods</h3> 50 stable RA patients (treated with Adalimumab, Etanercept or Methotrexate) and healthy volunteers with immunological memory to TB antigens were identified using an interferon-gamma ELISpot of peripheral blood. TST or saline (controls) was injected into the forearm of study participants and 3mm punch skin biopsies were taken from the injection site after 72 hours. Samples were collected for RNA analysis and histology. Genome wide transcriptional profiling was performed to compare gene expression changes in response to the TST challenge between treatment groups. As a surrogate marker for TNF activity the expression of TNF-regulated genes was quantified using a modular approach. <h3>Results</h3> Clinical TST responses were significantly diminished in RA patients compared to healthy controls. Anti-TNF therapy did not have a further significant effect on skin induration compared to those treated with methotrexate. However clinical TST skin induration did not correlate with peripheral blood response to TB antigens, as interferon-gamma responses to TB antigens in peripheral blood were not attenuated by rheumatoid disease or treatment. Genome wide transcriptional profiling showed that TNF was induced following the TST, and this was not attenuated by anti-TNF therapy, compared to RA patients treated with methotrexate or healthy controls. Furthermore, downstream activity of this induced TNF was preserved in patients on anti-TNF therapy. <h3>Conclusions</h3> Attenuated clinical TST responses have been previously shown in RA patients with active disease. Our results expand these findings to patients with stable disease, where the clinical TST responses were also diminished. Intriguingly, based on the transcriptional response to a TST challenge, we did not observe any reduction in TNF activity in patients on anti-TNF therapy. We conclude that anti-TNF therapy is unable to block a surge in TNF activity following an acute challenge. Therefore we infer that anti-TNF therapy is more likely to have biological effects on basal levels of TNF activity in steady state and rather than blocking TNF activity at the site of acute inflammation. <h3>Disclosure of Interest</h3> None declared
Double-Unit Cord Blood Transplantation for Hematological Malignancies in Japan: Multicenter Phase II Study (C-SHOT 0507)
Authors: Atsushi Wake, Shunro Kai, Masaya Okada, Mio Kurata, Yoshiko Atsuta, Jun Ishikawa, Masayuki Hino, Nobuyuki Aotsuka, Masaharu Kasai, Mahito Misawa, Shuichi Taniguchi, Shunichi Kato
Journal: Blood (2011)
Vascular Remodeling Underlies Re-Bleeding in Hemophilic Arthropathy
Authors: Annette Von Drygalski, Vikas Bhat, Merissa Olmer, Shweta Joshi, Donald Durden, Thomas J Cramer, Richard FW Barnes, Scott T Ball, Tudor H Hughes, Mauricio Silva, James V Luck, Randy Moore, Laurent O. Mosnier
Journal: Blood (2015)
High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Christopher P Fox, Ariane Boumendil, Herve Finel, Jian Jian Luan, Gulsan Sucak, Didier Blaise, Jurgen Finke, Karl-Heinz Pflüger, Hendrik Veelken, Norbert C Gorin, Xavier Poiré, Arnold Ganser, Norbert Schmitz, Peter Dreger, Anna Sureda
Journal: Blood (2012)
Clinical Outcome, Molecular and Gene Expression Analysis of 20 MLL-Rearranged AML from a Single Institution
Authors: Sergio Burillo-Sanz, Rosario Morales-Camacho, MT Vargas, Javier Sánchez, Jose Raul Garcia-Lozano, Teresa Caballero-Velazquez, Concepcion Prats-Martin, Olga Perez, Ricardo Bernal, Jose A. Perez-Simon
Journal: Blood (2015)
SAT0278 Association between Mucocutaneous Manifestations and Clinical and Immunological Characteristics in Juvenile-Onset Systemic Lupus
Authors: R. Fonseca, F. Aguiar, M. Rodrigues, I. Brito
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients diagnosed with juvenile-onset systemic lupus erythematosus (jSLE) often have skin and oral lesions as part of their presentation. It is suggested, in literature, that mucocutaneous involvement in jSLE may be associated with some antibodies and systemic disease and often require treatment with systemic immunosuppressive drugs in order to achieve adequate disease control. <h3>Objectives</h3> To assess mucocutaneous manifestations in jSLE and to study it9s associations with clinical and immunological characteristics. <h3>Methods</h3> Retrospective observational study was performed including consecutive patients with jSLE (disease onset before 16 years of age) followed in our Paediatric Rheumatology Unit. Clinical, demographic and laboratory characteristics were retrospectively collected by consulting the medical records. All patients fulfilled the clinical and laboratory criteria of the American College of Rheumatology (ACR). Patients with mucocutaneous manifestations were compared with others using Student t-test, Mann-Whitney test, Chi-square or Fisher test. (SPSS 23.0). Significance level was set as &lt;0.05. <h3>Results</h3> 38 patients were included, 92.1% (35) were female, with a mean age at diagnosis of 12.9 ± 3 years. Median period between onset of symptoms and diagnosis of SLE was 0.3 [0–1.2] years and median duration of follow-up was 14 [0.75–26]. 84.3% had mucocutaneous manifestations, (78.9% malar rash, 5.2% discoid rash, 70.3% photossensibility and 39.5% ulcers). 78.9% of the patients also had musculoskeletal symptoms, 63.2% haematological manifestations, 50% had renal involvement, 21% serositis and 13.2% neuropsychiatric involvement. Patients with mucocutaneous involvement had more frequently renal involvement (58% vs 14.2%, p=0.001), haematological manifestations (70.9% vs 28.5%, p=0.02), positive lupus anticoagulant (13.8% vs 4.3%, p=0.012), positive coombs test (59% vs 14.2%, p=0.04) and positive anti-SSa (35.4% vs 3.3%, p=0.04). SLEDAI and SLICC scores were comparable between the two groups. Analysing by type of skin involvement, patients with malar rash had also more frequently haematological involvement (76.7% vs 12.5%, p=0.002) and it was associated with the presence of anti-SSa (33.3% vs 12.5%, p=0.04). Patients with photossensibility had more frequently positive anti-SSa (34.5% vs 11.1%, p=0.029). Two patients (5.2%) had discoid lupus and 15 (39.5%) had ulcers but it was not associated with any other clinical or immunological manifestation. <h3>Conclusions</h3> Mucocutaneous are frequent manifestations in jSLE, and they are associated with active disease occurring frequently in patients with also haematological and renal manifestations. Anti-Ssa antibody is important in these patients as we have demonstrated it9s association with some particularly skin manifestations. <h3>Disclosure of Interest</h3> None declared
AB1031 Rheumatoid Arthritis, A Single-Center Egyptian Experience
Authors: M.M. Elfishawi, B.R. Sakr, M.H. El-Arousy, A.K. Hatw, A.N. Abdulkarim, A.B. Tammam, A.N. Kotp, M.E. Hamed, I.E. Genedy, E.D. El Desouky, Z.O. Nawito
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Epidemiology of Rheumatoid Arthritis (RA) is changing over time provided by several studies showing an increase in frequency and change in joint presentation.<sup>(1)</sup> Moreover, the characteristics of the disease may differ among different ethnicities and populations that necessitate studying each population to define its own pattern of RA. <h3>Objectives</h3> Our aim was to define disease characteristics in a cohort of Egyptian RA patients by retrospective analysis of their medical records through a period of 20 years. <h3>Methods</h3> Medical records of all cases who fulfilled the ACR 1987 criteria for diagnosis of RA starting from January 1995 till July 2015 were reviewed (n=3219). All patients were receiving medical follow–up at the Rheumatology outpatient clinic, Kasr AlAiny Hospital. Demographic data and disease characteristics were documented and statistically analyzed. <h3>Results</h3> A total of 3219 patients fulfilling the ACR 1987 criteria of RA were identified in the duration (1995–2015), 84% were females with mean age 48.8±13.8 that was not significantly lower than that of males 49.1±15.7 (p-value=0.62).The mean age of onset was 36.1±13.4 years and the mean disease duration was 12.9±7.9 years. Rheumatoid factor (RF) was detected in 49.9% of cases; erosions were found at diagnosis in 19.6% of patients.77.1% of RA cases presented with polyarticular and 22.9% with oligoarticular patterns. There was a significant increase by 0.12% in newly diagnosed cases annually (P-value=0.01) throughout the period studied (20y) (Fig. 1), however there was a significant decrement by 0.4% annually in females (p-value=0.02). On the other hand there was a significant steady increase in the mean age of onset by 0.2 year annually (P-value&lt;0.001). While, there was a steady decline in erosions by 0.5% annually (p-value=0.01) Females were more prone to have erosions although this was not found to be statistically significant; on the other hand RF was significantly higher in the erosive group (32.6%). Similarly the mean age at disease onset and age at diagnosis were statistically significantly higher in the erosive group (p-value=0.002 and p-value&lt;0.001 respectively). Regarding Extra-articular manifestations at the time of diagnosis, there was a significant decline in the presence of subcutaneous nodules and Sicca symptoms by0.4% &amp; 0.5% annually respectively (P-value=0.03). <h3>Conclusions</h3> The present study describes the demographic and disease characteristics of RA in the largest retrospective study as regards Egyptian RA patients. <h3>References</h3> Gibofsky, A. (2012). Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. The American journal of managed care, 18(13 Suppl), S295–302. <h3>Disclosure of Interest</h3> None declared
Distinct signaling programs control human hematopoietic stem cell survival and proliferation
Authors: David J. H. F. Knapp, Colin A. Hammond, Nima Aghaeepour, Paul H. Miller, Davide Pellacani, Philip A. Beer, Karen Sachs, Wenlian Qiao, WeiJia Wang, R. Keith Humphries, Guy Sauvageau, Peter W. Zandstra, Sean C. Bendall, Garry P. Nolan, Carl Hansen, Connie J. Eaves
Journal: Blood (2016)
PTH-086 Effect of Immunosuppressive Treatment on Interferon-Gamma Release Assays Prior to Biologic Treated Inflammatory Bowel Disease
Authors: S Bouri, AA Thi, P Wolfson, L Owen, A Abbara, L John, RN Davidson, AL Hart
Journal: Gut (2016)

<h3>Introduction</h3> Indeterminate interferon-gamma release assay (IGRA) results when screening for latent tuberculosis infection (LTBI)prior to biologic use in inflammatory bowel disease (IBD) may delay biologic treatment initiation. Concomitant steroids affect IGRA result, however the impact of other immunosuppressive medications is less clear. We determine the effect of immunosuppressives on results of IGRAs. <h3>Methods</h3> All patients treated with biologics from July 2013-November 2015 were identified from a pharmacy database. Electronic and clinical records were reviewed for IGRA result and concomitant immunosuppressive use. X2 was used to compare categorical data and univariate logistic regression using SPSS was used to determine likelihood of indeterminate tests with different immunomodulator medications (IMM). <h3>Results</h3> 247 patients with IBD had an IGRA. Mean age: 36.9 years (range 8–85) and 54% were male. 78/247 (32%) had an indeterminate result and 35/78 (45%) patients had a repeat test; 17/35 (49%) had a second indeterminate result. 181/247 (73%) received at least one IMM prior to screening and 66 patients (27%) were not on any IMM (IMM-free). In the IMM group: 121/181 (67%) patients had thiopurines, 18/181 (10%) had corticosteroids, 25/181 (14%) had both, 9/181 (5%) had methotrexate and 7/181 (4%) had other IMMs at screening. 72/181 (40%) had a first indeterminate IGRA 59/181 (33%) had a second indeterminate result. In the IMM-free group: 6/66 (9.0%) had an indeterminate IGRA. Patients in IMM group were more likely to have an indeterminate results than patients in IMM-free group (33% v 9.0%, p = 0.00001). Each separate IMM group was more likely to be associated with an indeterminate IGRA result compared with those in IMM-free group: thiopurines (23%) p = 0.020, steroids (42%) p = 0.001, thiopurines and steroids (64%) p = 0.001, other (43%) p = 0.01 and methotrexate (44%) p = 0.008). The combination of steroids and thiopurines together was the strongest factor associated with an indeterminate result. High dose (Prednisolone &gt;20 mg or intravenous Hydrocortisone) and low dose steroids (Prednisolone &lt;20 mg or Budesonide) were equally likely to cause an indeterminate result (66.6% v 50.0%, p = 0.68). <h3>Conclusion</h3> A combination of thiopurines and steroids gave the highest likelihood of an indeterminate IGRA result, although significant results occurred with all IMMs. This has implications for LTBI screening in IBD patients. Guidelines to address indeterminate IGRA results, perhaps with more focus on epidemiological risk may be helpful. There is an unmet need to have improved assessment tools for TB in patients on IMMs. <h3>Disclosure of Interest</h3> None Declared